Digital Pathology Market Size

The global Digital Pathology market reached US$ 1.33 billion in 2025 and is expected to reach US$ 6.82 billion by 2035, growing with a CAGR of  18.4% during the forecast period 2026-2035. 

The increasing burden of cancer worldwide will continue to fuel the need for digital pathology, with an estimated 20.6 million cases of cancer being diagnosed globally every year, according to IARC GLOBOCAN 2024 data. The growing trend towards precision oncology and biomarker-driven decision making will further fuel the adoption of digital pathology. The increasing adoption of whole slide imaging (WSI), artificial intelligence (AI) and computational pathology technologies allows for not only accelerated and standardized diagnoses but also increased efficiency of workflow processes within hospitals, laboratories and academic medical centers. Pharmaceutical and biotechnological companies are also increasingly utilizing digital pathology technologies to discover new biomarkers and conduct clinical trials.

In addition, the market is being driven by the fast-paced digitalization of pathology laboratories and increasing investment in enterprise pathology systems, cloud-based image management and artificial intelligence-enabled diagnostic tools. The rise in the number of biomarker-based oncology clinical trials is driving the need for digitalized tissue examination and pathology data management. The ongoing improvements in validation of artificial intelligence, automation of laboratories and the formation of integrated pathology ecosystems would likely facilitate the uptake of digital pathology technology in clinical diagnostics and life sciences research. According to the International Agency for Research on Cancer (IARC), the incidence of cancer is expected to surpass 35 million cases per year by 2050.

Digital Pathology Market Key Takeaways

• North America held 40.1% share of the total Digital Pathology Market in 2025 based on WSI implementation, increasing approvals of digital pathology tools and rising investments in AI technology and precision oncology.
• The Asia-Pacific region will emerge as the leading region at a CAGR for the forecast period of 2026-2035 due to digitization of the healthcare industry, rising cases of cancer, lab modernization plans and use of AI-powered pathology platforms in China, Japan, South Korea and India.
• The WSI Systems market segment held about 39.3% share of the Global Digital Pathology Market in 2025 due to increased preference for high resolution slide imaging in hospitals, diagnostic centers, academic medical centers and research facilities.
• The AI Image Analysis Software market segment is forecast to witness an approximate CAGR of 21.8% between 2026-2035 owing to growing use of computational pathology, biomarker quantification, workflow management, cloud-based image analysis and precision oncology.
• More than 70% of oncology clinical trials around the world utilize patient biomarker selection, which leads to higher demand for digital pathology in the sphere of companion diagnostics, tissue image analysis and translational research.

Digital Pathology Industry Trends and Strategic Insights

• The development and usage of AI-powered computational pathology have been identified as the main trend in the industry, providing automation of medical image interpretation, biomarker quantification, predictive diagnostics, etc.
• Digital pathology is becoming more widely used across the enterprise, as health facilities invest in  cloud-based solutions that provide remote pathology analysis and interoperable digital workflows to improve operational efficiency and diagnostic collaboration.
• The rise of precision oncology has increased the strategic value of digital pathology, including companion diagnostics, biomarker-led patient identification and clinical trials of targeted and immuno-oncology therapeutics.
• There has been an increasing number of strategic partnerships among pathology vendors, AI developers and the pharmaceutical industry, pushing innovations in AI-supported diagnostics, clinically validated applications and comprehensive solutions in precision medicine.
• Competition is moving to the realm of ecosystems rather than individual products, with leaders setting their differences through comprehensive solutions of WSI, AI analysis, cloud services, cybersecurity and connectivity with LIS/HIS systems.

Digital Pathology Market Scope

Why does this report matter in 2026?

2026 is an important year for the Digital Pathology Market due to the growing inclination towards switching from the use of traditional pathology processes to digital, which can benefit from advanced artificial intelligence. There is a growing popularity of WSI, computational pathology and cloud-based systems which provide greater accuracy and efficiency within laboratories and allow remote colloboration. In addition, the increased commercialization of AI-powered pathology solutions, increased number of applications within precision oncology and demand for companion diagnostics are providing further opportunities.

This report is aimed at giving you an all-around assessment of the market’s current status as well as its future possibilities, which would help the interested parties pinpoint the areas with higher growth potential, the upcoming technological innovations, regional opportunities and the best strategic approaches for competition. It gives insights into the trends associated with market dynamics, technology adoption, regulatory environment, partnerships and investments, thus giving you a competitive edge over your competitors.

Digital Pathology Market White Space & Investment Opportunities

• Pathology solutions in AI technology targeted at community hospitals and mid-sized laboratories constitute a notable white space since the uptake of the solutions has been limited mostly to large institutions because of costs and infrastructure.
• There is an enormous investment opportunity in the creation of cloud-native pathology ecosystems and seamless integration of LIS, HIS and EHR systems due to rising demand for enterprise digital workflows and collaboration.
• Digital pathology solutions for rare diseases, infectious diseases and non-oncology applications remain underpenetrated, creating opportunities to expand AI-assisted diagnostics beyond the currently dominant oncology segment.
• Predictive and multimodal pathology platforms through integration of pathology with genomics, radiology and clinical data also provide good investment potential in the emerging sector in view of its role in precision medicine and treatment planning.
• AI-based pathology platforms created for use in decentralized telepathology and telemedicine services in developing countries will provide significant opportunities going forward due to improvements in healthcare infrastructure, Internet connectivity and digital health technologies.

Digital Pathology Future Market Transformation

Over the next 10 years, the Digital Pathology Market is set to experience a drastic change where the evolution of pathology laboratories will be from isolated digitization of slides to a state-of-the-art artificial intelligence-powered ecosystem for diagnostics. Artificial Intelligence (AI), Whole Slide Imaging (WSI), Computational Pathology and cloud-based platforms will facilitate faster and more accurate standardizations along with increased efficiency in the diagnosis process while enabling collaborative working between different experts remotely. Combination of digital pathology with precision oncology, companion diagnostics, genomics and digital health solutions will increase its scope even further.

There would also be a shift towards digital pathology platforms from solutions that are focused on hardware. This includes digital pathology platforms which integrate scanning technology, AI analytics, cloud image management, LIS, HIS, EHR integration and cybersecurity. With increasing regulatory approval and continued investment in digital technology by health care organizations, digital pathology will be an integral part of clinical diagnostics in the coming years. This would create revenue opportunities and also help in distinguishing competitors within the global pathology market.

Digital Pathology Market Buyer Decision-Making Criteria

Healthcare organizations, laboratories, pharma businesses and research organizations assess digital pathology solutions for their ability to increase the accuracy of diagnoses, optimize workflow processes and facilitate a digital transformation process. The purchasing criteria include such aspects as artificial intelligence functionality, image quality, compatibility with current healthcare information technology systems, regulatory compliance, security, scalability and total cost of ownership. Another criterion is the capability of the vendor to provide the enterprise-level solution with good technical support and updates.

Major Buyer Decision-Making Criteria

• Diagnostic accuracy, AI capabilities and clinical validation
• Whole-Slide Imaging (WSI) quality, scanner performance and workflow efficiency
• Interoperability with LIS, HIS, EHR and enterprise digital pathology systems
• Regulatory compliance, cybersecurity and data privacy protection
• Total cost of ownership, scalability and vendor support services

Digital Pathology Market Economic & Investment Analysis

The Digital Pathology Market offers strong long-term economic potential, driven by rising healthcare expenditure, increasing laboratory digitalization and growing adoption of AI-enabled diagnostic technologies. Investment in whole slide imaging (WSI), computational pathology, cloud-based imaging management and AI-driven pathology software is increasing as healthcare establishments seek to improve diagnostic accuracy and flexibility of operations and remote collaboration options. Investments of pharmaceutical and biotechnology companies in digital pathology are also on the rise due to the importance of biomarker discovery and companion diagnostics which creates commercial opportunities for providers in this field. The expansion of regulatory approvals and strategic partnerships between healthcare companies and developers of AI algorithms boosts investment prospects in the digital pathology market.

The market from an economic point of view is changing its nature from a business model where profit generation is tied to hardware sales into one that revolves around recurring revenues resulting from software licensing, cloud computing, AI data analysis and enterprise services. Even though high installation costs, investment in IT infrastructure and compliance continue to be major economic factors, the ROI is good due to such long-term advantages as increased laboratory efficiency, decreased time to diagnose, efficient resource management and scalability of digital processes. Companies that provide such digital pathology ecosystems are likely to attract more investments.

Digital Pathology Investment Trends in the Market

• AI-enabled Pathology Software, along with Computational Pathology, are receiving significant investments, with capital being allocated towards automated image analysis, biomarker quantification, clinical decision support and workflow automation.
• Funding towards cloud-ready digital pathology platforms is growing, which helps in providing image management, telepathology solutions, cloud storage and collaboration among multiple sites within the healthcare network.
• Increased investment is being made by pharmaceutical companies and biotechnology firms in digital pathology in order to develop precision oncology and companion diagnostics.
• Strategic investments are becoming more and more aligned with the themes of interoperability and enterprise integration, which include improved interoperability between digital pathology solutions, Laboratory Information Systems (LIS), Hospital Information Systems (HIS), Electronic Health Records (EHR) and laboratory automation solutions.
• M&A and partnerships are becoming one of the new trends in terms of financing, because established diagnostics players join forces with AI and digital health startups to enhance their digital pathology capabilities and commercialize new generation of diagnostic solutions.

Strategic Indicators For Digital Pathology Market

High Regulation Impact

The Digital Pathology Market is defined by its high regulatory influence since the digital pathology solutions, whole-slide imaging scanners and AI diagnostic applications need thorough validation and regulatory clearance prior to being made available for use. FDA 510(k), European Union IVDR and HIPAA or GDPR regulatory frameworks have a strong bearing on the development, marketing and commercialization of products. Moreover, increasing regulatory concerns regarding the performance and security of AI algorithms make compliance with the regulations essential for long-term success.

High Investment Activity

Digital Pathology Market is witnessing significant levels of investments driven by growing levels of capital allocation from healthcare organizations, diagnostic laboratories, life sciences companies and institutional investors aiming at transforming the way pathology is delivered. Growing focus is being witnessed towards laboratory-wide digitalization, expansion of digital diagnosis capabilities, clinical validation and marketing of the solutions as well as geographical expansion of the market. Growing levels of mergers and acquisitions, venture capital investments and partnerships in the form of collaborations are bolstering product development pipelines and helping accelerate the commercialization of next-generation digital pathology solutions.

Supply Chain Disruption

Moderate supply chain risk exists in the Digital Pathology Market based on its reliance on expensive optical parts, CMOS image sensors, high-quality scanners, semiconductor chips, computing equipment supported by GPUs and high-performance storage capabilities needed for WSI and AI-powered pathology operations. The delays in sourcing these necessary products will increase the time involved in the production and deployment of digital pathology equipment for hospitals and diagnostic facilities. Furthermore, growing requirement for computing capacity to perform AI-powered image processing has further raised the risk of hardware availability in the market.

Pricing Volatility

The Digital Pathology Market experiences moderate pricing volatility,due to the changing prices of semiconductor chips, CMOS imaging sensors, precision optical components, GPUs, as well as enterprise storage used in whole slide imaging (WSI) platforms. High throughput digital pathology scanners usually range from US$100,000 to US$400,000 in price, while artificial intelligent pathology software is offered through licensing, causing price variations based on the level of deployment and functionality applied. Also, there are costs of cloud storage and image administration, as much whole slide images are produced, that account for differences in total costs of ownership between healthcare organizations. Even if rising competition and SaaS-based pricing makes things easier with pricing issues, advanced AI-enabled digital pathology solutions continue to offer high prices due to their innovativeness, clinical trials and compliance with rules and regulations.

Procurement Pressure

High procurement pressures characterize the Digital Pathology Market because hospitals, integrated healthcare organizations and reference laboratories are consolidating procurement efforts and using competitive tendering processes. The market buyers want turn-key digital pathology offerings with clinical validation, service arrangements, implementation services and scalability rather than just scanners and standalone systems. With an increase in the sophistication of procurement processes and scrutiny over spending budgets, the vendors are being pressured to provide demonstrable operational efficiency and ROI to secure lucrative deals.

New Technology Adoption

The Digital Pathology Market is seeing high levels of technology adoption due to the migration of healthcare organizations from their conventional stand-alone digital imaging solutions towards more integrated and enterprise grade artificial intelligence powered pathology ecosystem. There is an increasing trend among laboratories towards purchasing of artificial intelligence-powered and validated algorithms, cloud-based image management solution along with workflow automation and interoperable digital pathology solutions. The increasing adoption rate is being propelled by the increasing regulatory approval for use of artificial intelligence in the field of pathology along with investments in precision oncology space.

Regional Expansion Opportunity

The Digital Pathology Market shows promise for geographical expansion into regions such as Asia Pacific, Latin America and Middle East regions, driven by the lack of pathologists in the region, high prevalence of cancers and shortage of specialist pathologists, which has been rapidly increasing the use of telepathology and digital pathology techniques in these regions. The investments being made in cancer centers, reference laboratories and precision medicine initiatives have been raising the demand for whole slide imaging systems and artificial intelligence-based diagnostic systems. The suppliers are establishing their geographical footprints through strategic partnerships with distributors and healthcare facilities in the regions.

Government Policy Support

The role of government policy backing as a key driver for the Digital Pathology Market is gaining importance through cancer control strategies by governments, digitization strategies within health care systems and development of the required framework for precision medicine. Support from the government side for laboratory upgrade, increasing telepathology networks and digitizing pathology services is helping the market grow and develop rapidly. Also, the government is backing research in collaboration with private firms on integrating AI-based pathology into the clinical field.

Pricing Intelligence

Pricing intelligence in the digital pathology market indicates the use of a value-based pricing model that accounts for many factors, such as throughput capacity of the scanners, image clarity, AI capabilities, methods of installation and requirements for enterprise integration. The price for entry-level whole slide scanners usually falls between US$50,000 and US$100,000, whereas high throughput clinical scanners cost between US$150,000 and US$400,000 on average. Apart from the covered costs, buyers consider the recurring expenses related to several processes, such as the use of image management software, the need for cloud storage, implementation and maintenance issues, thus affecting TCO considerations. As competition between vendors becomes more severe, they start applying such mechanisms as subscription licensing, enterprise contracts and bundles of services in order to stay competitive.

AI Impact Analysis of the Digital Pathology Market

There are significant shifts taking place in the Digital Pathology Market owing to the development of artificial intelligence, which makes it possible to have automatic image analysis, increase in the accuracy of diagnosis and increase the efficiency in pathological work. With AI algorithms, it becomes easier to detect tissue abnormalities, measure biomarker levels, select difficult cases for further investigation and aid pathologists in diagnosing cancerous and other diseases more reliably.

In addition to diagnostics, the use of AI in tissue analysis, biomarker identification and digital pathology-driven clinical trials is helping speed up pharmaceutical research and drug discovery process. The increasing adoption of AI along with whole slide imaging (WSI), cloud-enabled pathology solution platforms and Laboratory Information System (LIS) systems is creating an integrated digital network to enhance collaboration and operational efficiencies in the healthcare ecosystem. AI is also affecting market competition with the vendors becoming distinctive in terms of the availability of AI-driven pathology solution platform and predictive analytic solutions and also regulator approved clinical decision support solutions. Going ahead, AI would be among the most impactful technology for the market.

Disruption Analysis of Digital Pathology Market

The market of digital pathology is undergoing tremendous disruption because the application of AI, WSI, cloud computing and computational pathology is bringing about the adoption of smarter pathology ecosystem that is replacing traditional pathology processes that relied on microscopes with more intelligent processes that embrace digitization. Processes such as AI-enabled image analysis, automated quantification of biomarkers and the predictive diagnostic algorithms are contributing to accuracy of diagnostics and standardized pathology procedures.

Disruption in the field can also be seen with respect to the move from stand-alone pathology equipment towards integrated digital pathology solutions consisting of scanning, artificial intelligence software, cloud image management and the ability to interface with LIS and HIS platforms. Competition in the industry will now also involve software innovations in addition to imaging innovations. Competitive pressure will be coming from firms with an artificial intelligence focus and digital health solutions that will lead to further partnership, acquisitions and product innovation within the industry.

Digital Pathology Market BCG Matrix: Company Evaluation

STAR

Roche Diagnostics, Leica Biosystems (Danaher) and Philips Healthcare belong to the Star category because of their significant market share globally, extensive range of digital pathology products and constant innovations in WSI technology, AI image analysis software and enterprise pathology systems. Because of their wide range of regulatory approvals, well-established customer base and collaborations in precision medicine and companion diagnostics, they can maintain their leadership in digital pathology that is growing at a fast pace.

POTENTIAL

Proscia, PathAI, Paige, Aiforia Technologies and Indica Labs fall under the category of Potential due to the fact that even though they have a high-growth potential in the rapidly developing market, they currently lack market power compared to established firms as their market presence is limited. As they continue to increase partnerships and build regulatory validation, they will become stronger competitors in the field.

Digital Pathology Market Dynamics 

Driver Impact Analysis

Driver: Growing Adoption of AI-Enabled Whole Slide Imaging (WSI) and Digital Pathology Platforms

The increased use of AI-based Whole Slide Imaging (WSI) systems and digital pathology solutions is driving the Digital Pathology market growth. The use of WSI enables the pathology slides to be converted into digitized imaging with higher resolution for storage, analysis and even sharing. With AI-based image analysis, the process becomes more accurate and faster. There is increased demand for oncology diagnosis, precision medicine, biomarkers and companion diagnostics which is resulting in the adoption of digital pathology solutions across hospitals, laboratories, pharmaceuticals and research institutions. The use of cloud-based systems and telepathology solutions facilitates easier collaboration among pathologists who are geographically distant from each other, thereby assisting in overcoming labor shortage challenges. Growth in approval of AI-based solutions for pathology solutions and investments made by the stakeholders in digitalizing the process will result in increased adoption of digital pathology platforms during the forecast period.

Restraint Impact Analysis

Restraint: High Capital Costs and Complex IT Infrastructure Requirements

Implementation of digital pathology has been hindered by the high costs involved in deployment and the need for advanced IT infrastructure. Creation of an environment of digital pathology involves huge investments in whole-slide scanners, image management tools, large scale data storage systems, artificial intelligence and secure integration with LIS and HIS. Moreover, big image files have the need for advanced storage capacity, fast networking and advanced cybersecurity, which increase the cost of operation. Other expenses include validation, compliance with regulations, training of the workforce and maintenance of the equipment among others. Financial and technical difficulties of implementing digital pathology are especially challenging for small and medium healthcare organizations.

Digital Pathology Market Segment Analysis     

The global Digital Pathology market is segmented based on the Product, Technology, Deployment Mode, Application, Disease Area, End-User and region. 

By Technology

Whole-Slide Imaging (WSI) Systems Remain the Cornerstone of Digital Pathology

The Whole-Slide Imaging (WSI) Systems led the Digital Pathology Market during 2025, commanding around 39.3% share of the global market size due to its significance in changing traditional glass slides to the digital images. The whole slide imaging system is the building block of the digital pathology which allows various applications like telepathology, Artificial Intelligence (AI)-based image analysis, precision oncology and seamless integration into laboratory information systems of the hospitals, diagnostics laboratories and academic medical centers.

By Product

Growing Adoption of AI Image Analysis Fuels Future Market Expansion

The AI-Based Image Analysis Solution Market is estimated to grow at a rate of about 21.8% over the forecast period 2026-2035 as more and more people start opting for computational pathology, automated tissue examination, biomarker assessment and clinical decision support solutions. With an increase in demand for automation, precision medicine, cloud-based digital pathology solution, as well as with continuous evolution in the domain of AI and machine learning, more applications of AI-driven pathology solutions will be seen in future.

Digital Pathology Market Geographical Penetration

U.S. Digital Pathology Market Landscape

United States dominates the Digital Pathology Market, thanks to its well-developed pathology framework, commercial availability of whole slide imaging technologies and dominance in artificial intelligence-based diagnostics systems. This market boasts a thriving ecosystem of top universities with medical schools, integrated delivery networks (IDN), independent reference labs, pharmaceutical companies and AI vendors that make use of digital pathology in their daily activities, including diagnostics and biomarker discovery, companion diagnostics and even clinical trials. The use of FDA cleared primary diagnoses systems, as well as precision medicine and the move towards digital pathology workflows, boosts the clinical application of such technology in healthcare institutions in the United States. Another factor that makes US dominate the market is the existence of big technology players and continuous investments in computational pathology, as well as tight collaboration between healthcare providers and software developers.

Japan Digital Pathology Market Outlook

Japan has proved to be a major Digital Pathology market in the Asia-Pacific region due to the presence of an advanced health care system, a high level of pathology expertise and adoption of AI diagnostics technology. Aging population and rise in the burden of cancer cases in Japan are contributing to the rapid need of efficiency in pathology workflow processes, resulting in the adoption of whole-slide imaging (WSI), computational pathology and digital laboratory systems in hospitals and university hospitals. Digital Pathology is being increasingly adopted for precision oncology, biomarkers identification, clinical research and pharmaceutical drug discovery through collaborations among healthcare service providers, academic institutes and life sciences companies in the region

China Digital Pathology Market Trends

Digital Pathology Market in China is considered as one of the fast-growing ones owing to growing digitalization in healthcare, developing network of tertiary hospitals and use of new AI-driven diagnostics methods. The country sees the rise of WSI devices, cloud-connected digital pathology platform implementations and other innovations that will improve diagnostic capabilities and cope with the increasing incidence of cancer. Growing investment into AI and precision medicine, as well as into lab infrastructure modernization drives further commercialization of computational pathology solutions and at the same time there is significant progress in terms of AI-driven imaging and digital pathology software by local IT firms. The continued development of regional pathology networks and digital laboratory workflows will further boost the leading role of China in the global market for digital pathology solutions.

Germany Digital Pathology Market Trends

Germany is among the most significant digital pathology markets in Europe based on its established pathology lab network, advanced university hospitals and precision diagnostics initiatives. There is currently an increase in the adoption of whole-slide imaging (WSI), image analysis aided by artificial intelligence and computational pathology for the purpose of diagnosing cancer, assessing biomarkers and conducting translational studies. The introduction of digital pathology solutions continues to gain traction among academic medical centers and reference labs, thanks to the increasing use of laboratory automation, interoperability with health information systems and the adherence to the EU In Vitro Diagnostic Regulation (IVDR). Effective cooperation among healthcare organizations, research organizations and life science organizations is contributing further to the development of digital pathology solutions in Germany.

Digital Pathology Market Competitive Landscape

• The leading companies in this field are competing on digital pathology solutions that incorporate WSI scanners, image management systems, artificial intelligence (AI)-enabled image analysis tools and LIS integration, enabling complete end-to-end pathology workflows.
• The main competition driver is the use of AI, with various vendors like Paige AI, PathAI, Proscia, Aiforia and Visiopharm having algorithms for cancer diagnosis, biomarker quantification and automation of work flow processes, improving their clinical value.
• Regulatory clearances are critical obstacles in the market and FDA and CE-IVD clearances have become obligatory for the adoption of the products in routine diagnostics, especially in oncology, companion diagnostics and precision medicine.
• The formation of strategic alliances among manufacturers of scanning machines, artificial intelligence software, pharmaceutical companies and healthcare organizations is promoting further development of companion diagnostics and digital biomarkers, which will facilitate the widespread implementation of digital pathology in clinical trials and precision oncology.
• The rivalry now centers on enterprise-level solutions, with companies improving their services in cloud-based image management, interoperability with hospital information systems (HIS/LIS), cybersecurity and networked collaboration among pathologists in various sites.

Key Companies

• Leica Biosystems (Danaher Corporation) (United States)
• Philips Healthcare (Netherlands)
• Roche Diagnostics (Switzerland)
• Hamamatsu Photonics (Japan)
• Fujifilm Holdings Corporation (Japan)
• Konica Minolta, Inc. (Japan)
• Carl Zeiss Meditec AG (Germany)
• Motic (China)
• Huron Digital Pathology Inc. (Canada)
• Visiopharm A/S (Denmark)
• Indica Labs, Inc. (United States)
• Proscia Inc. (United States)
• PathAI, Inc. (United States)
• Paige AI, Inc. (United States)
• Sectra AB (Sweden)
• Aiforia Technologies Plc (Finland)
• Thermo Fisher Scientific Inc. (United States)
• Agilent Technologies, Inc. (United States)
• Evident Corporation (Japan)
• Epredia (United States)

Digital Pathology Market Major Pain Points

• The high capital requirement associated with the purchase of WSI scanners, powerful servers and petabyte-level image storage has become a barrier to adoption, especially in small and medium-sized pathology labs.
• Non-interoperability among WSI scanners, IMS, LIS and EHR is still a challenge that leads to fragmentation in digital pathology workflows, thus complicating its implementation.
• Validation and approval of artificial intelligence powered pathology algorithms in routine clinical practice take much time and hinder commercial use and broader distribution outside selective applications.
• Processing gigabytes of whole-slide images (WSIs) demands significant bandwidth and long-term storage capabilities as well as cloud security systems, thus raising operational expenses.
• The reluctance to switch from traditional microscopy to digital pathology along with the necessity of training pathologists hinders the transition to digital pathology in enterprises.

Digital Pathology Market Recent Developments

• January 2025: The FDA granted clearance under the 510(k) procedure to Roche Diagnostics VENTANA DP 600 slide scanner with regard to high throughput scanning of slides, as part of Roche Digital Pathology Dx offering used for diagnostic purposes and high-throughput pathology processes.
• May 2026: Roche Diagnostics announced a definitive agreement to acquire PathAI, thus enhancing their offering of artificial intelligence-based digital pathology, image analysis and companion diagnostics technologies.
• June 2026: Proscia released the fifth generation of its Concentriq digital pathology software, incorporating an AI-native design that allows for enterprise pathology workflows, clinical diagnostic analysis and biopharmaceutical research.
• June 2026: Leica Biosystems extended its partnership with AstraZeneca and Daiichi Sankyo for the development of AI-based companion diagnostics and digital pathology systems for precision oncology.
• March 2026: Philips Healthcare introduced an extended range of digital pathology solutions with the introduction of Philips IntelliSite Pathology Solution running on HealthSuite, which is powered by Amazon Web Services (AWS). This solution helped pathologists to store and manage their whole-slide imaging data in a secure manner.

Analyst View / Opinion on Digital Pathology Market

• The field of digital pathology is gradually evolving from simple slide digitization to AI-enabled diagnostic ecosystems, with an integration of WSI, computational pathology and AI image analysis becoming critical aspects of clinical diagnostics and precision medicine.
• The role of artificial intelligence in diagnostics will become even more pronounced as vendors will increasingly turn their attention to developing validated algorithms for cancer detection, biomarker measurement, prioritizing cases and automating pathology workflow.
• Onco-pathology will maintain its dominance in terms of revenue generated, due to the increasing number of uses of digital pathology for companion diagnostics, biomarker testing and clinical trials, especially immuno-oncology and targeted therapies.
• The uptake of digital pathology at enterprise level will increase, with the increase in investment towards cloud image management, integration with LIS and HIS and remote collaboration for pathology across multi-site healthcare enterprises.
• Market leadership will be sustained by platform capabilities and not individual product offerings; firms that can integrate all high throughput scanners, AI software, clinical applications approved by regulations and interoperable digital workflow platforms are likely to have an edge over their competitors.

Digital Pathology Market Target Audience 

Why Choose DATAM?

• Data-Driven insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. The approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. The personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. The insights complement and go beyond what is typically available in generic databases.

What DATAM Uniquely Provides

• Proprietary methodology for market size estimation and market forecasting, which utilizes primary interviews, secondary information, mapping of companies' revenues, technology adoption patterns and demand-side validation to generate very accurate market estimates and forecasts.
• Benchmarking of deep technologies in digital pathology, including whole slide imaging (WSI), AI-driven pathology software, computational pathology platforms, cloud deployment strategies and interop capabilities of top vendors.
• Beyond market shares, competitive intelligence that includes product portfolio benchmarking, innovation activities, patents and partnerships, regulatory environment and positioning strategies of key players in the market.
• Strategic decision-making insights offering opportunity mapping based on the application, the type of illness, end-user and the geographic area, supported by various analyses and predictions regarding the impact of the product, adoption trends, areas of investment and growth potential.
• Ongoing monitoring of market movements helping the clients to get timely updates regarding product launches, approvals by the FDA/CE, mergers and acquisitions, joint ventures and commercialization of new technologies.